176 related articles for article (PubMed ID: 18224343)
1. Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study.
Yoshikawa N; Nakanishi K; Ishikura K; Hataya H; Iijima K; Honda M;
Pediatr Nephrol; 2008 May; 23(5):757-63. PubMed ID: 18224343
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT.
Shima Y; Nakanishi K; Kaku Y; Ishikura K; Hataya H; Matsuyama T; Honda M; Sako M; Nozu K; Tanaka R; Iijima K; Yoshikawa N;
Pediatr Nephrol; 2018 Nov; 33(11):2103-2112. PubMed ID: 29987456
[TBL] [Abstract][Full Text] [Related]
3. Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy.
Shima Y; Nakanishi K; Kamei K; Togawa H; Nozu K; Tanaka R; Sasaki S; Iijima K; Yoshikawa N
Nephrol Dial Transplant; 2011 Jan; 26(1):163-9. PubMed ID: 20601366
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of a randomized controlled trial in childhood IgA nephropathy.
Kamei K; Nakanishi K; Ito S; Saito M; Sako M; Ishikura K; Hataya H; Honda M; Iijima K; Yoshikawa N;
Clin J Am Soc Nephrol; 2011 Jun; 6(6):1301-7. PubMed ID: 21493743
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group.
Yoshikawa N; Ito H; Sakai T; Takekoshi Y; Honda M; Awazu M; Ito K; Iitaka K; Koitabashi Y; Yamaoka K; Nakagawa K; Nakamura H; Matsuyama S; Seino Y; Takeda N; Hattori S; Ninomiya M
J Am Soc Nephrol; 1999 Jan; 10(1):101-9. PubMed ID: 9890315
[TBL] [Abstract][Full Text] [Related]
6. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial.
Yoshikawa N; Honda M; Iijima K; Awazu M; Hattori S; Nakanishi K; Ito H;
Clin J Am Soc Nephrol; 2006 May; 1(3):511-7. PubMed ID: 17699253
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of prednisolone and mizoribine therapy for diffuse IgA nephropathy.
Kawasaki Y; Suzuki J; Sakai N; Etoh S; Murai H; Nozawa R; Suzuki H
Am J Nephrol; 2004; 24(1):147-53. PubMed ID: 14726626
[TBL] [Abstract][Full Text] [Related]
8. Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy.
Yagi K; Okada M; Yanagida H; Kuwajima H; Ikeda M; Sugimoto K; Takemura T
Clin Exp Nephrol; 2003 Dec; 7(4):270-4. PubMed ID: 14712355
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy--is it relevant for adult patients?
Yoshikawa N; Ito H
Nephrol Dial Transplant; 1999 May; 14(5):1097-9. PubMed ID: 10344344
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study.
Xie Y; Huang S; Wang L; Miao L; Zhang A; Li Y; Wu X; Wang L; Liu S; Lie C; Chen P; Chen X
Am J Med Sci; 2011 May; 341(5):367-72. PubMed ID: 21293249
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of multidrug therapy combined with mizoribine in children with diffuse IgA nephropathy in comparison with multidrug therapy without mizoribine and with methylprednisolone pulse therapy.
Kawasaki Y; Hosoya M; Suzuki J; Onishi N; Takahashi A; Isome M; Nozawa R; Suzuki H
Am J Nephrol; 2004; 24(6):576-81. PubMed ID: 15550753
[TBL] [Abstract][Full Text] [Related]
12. Serum IgA/C3 and glomerular C3 staining predict severity of IgA nephropathy.
Kawasaki Y; Maeda R; Ohara S; Suyama K; Hosoya M
Pediatr Int; 2018 Feb; 60(2):162-167. PubMed ID: 29178575
[TBL] [Abstract][Full Text] [Related]
13. Mizoribine for relapsed proteinuria in an adult IgA nephropathy patient.
Tokunaga M; Tamura M; Kabashima N; Serino R; Shibata T; Matsumoto M; Miyamoto T; Miyazaki M; Furuno Y; Nakamata J; Takeuchi M; Abe H; Okazaki M; Otsuji Y
Clin Nephrol; 2008 Nov; 70(5):445-6. PubMed ID: 19000548
[No Abstract] [Full Text] [Related]
14. Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy.
Kamei K; Nakanishi K; Ito S; Ishikura K; Hataya H; Honda M; Nozu K; Iijima K; Shima Y; Yoshikawa N;
Pediatr Nephrol; 2015 Jun; 30(6):961-7. PubMed ID: 25487669
[TBL] [Abstract][Full Text] [Related]
15. Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study).
Shima Y; Nakanishi K; Sako M; Saito-Oba M; Hamasaki Y; Hataya H; Honda M; Kamei K; Ishikura K; Ito S; Kaito H; Tanaka R; Nozu K; Nakamura H; Ohashi Y; Iijima K; Yoshikawa N;
Pediatr Nephrol; 2019 May; 34(5):837-846. PubMed ID: 30284023
[TBL] [Abstract][Full Text] [Related]
16. Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy.
Ikezumi Y; Suzuki T; Karasawa T; Kawachi H; Nikolic-Paterson DJ; Uchiyama M
Pediatr Nephrol; 2008 Apr; 23(4):645-50. PubMed ID: 18038158
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of steroid pulse therapy in combination with mizoribine following tonsillectomy for immunoglobulin A nephropathy in renally impaired patients.
Kaneko T; Shimizu A; Tsuruoka S; Iino Y; Katayama Y
J Nippon Med Sch; 2013; 80(4):279-86. PubMed ID: 23995570
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study.
Nakanishi K; Iijima K; Ishikura K; Hataya H; Awazu M; Sako M; Honda M; Yoshikawa N;
Pediatr Nephrol; 2009 Apr; 24(4):845-9. PubMed ID: 18825420
[TBL] [Abstract][Full Text] [Related]
19. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy.
Ballardie FW; Roberts ISD
J Am Soc Nephrol; 2002 Jan; 13(1):142-148. PubMed ID: 11752031
[TBL] [Abstract][Full Text] [Related]
20. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
McIntyre CW; Fluck RJ; Lambie SH
Clin Nephrol; 2001 Sep; 56(3):193-8. PubMed ID: 11597033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
